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ABSTRACT
The impact of Cassytha filiformis butanol fraction to the pregnancy and fetal development had been conducted. The fertilized mice were treated with 
butanol fraction of C. filiformis at doses of 2.5; 5; 10; and 20 mg/kg of body weight (BW) orally for 5 consecutive days during first, second, and third 
periods of pregnancy. Parent BW was monitored and the fetal number, BW, death and/or resorptive site and defect were measured. ANOVA followed 
by Duncan multiple range test (significance at p<0.05) was performed to analyze data. The parent weight was reduced according to fraction dose 
and the period of pregnancy and the interaction of those factors (p<0.01). Only one mouse treated during the first period became pregnant with less 
fetus number (p<0.05) but all of treated during the second and third period but death, resorptive site and underdeveloped fetus were found. These 
indicated the butanol fraction of C. filiformis produced infertility and slowed pregnancy development and produce fetal defect on mice.
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INTRODUCTION
The world is witnessing an unprecedented growth in the usage of 
herbal products. India, for example, is a mother hub for natural herb-
based science [1]. Since 2007, Indonesian government has released a 
regulation for the traditional medicine policy to develop and increase 
their quality, safety, and efficacy [2]. Unfortunately, the number of 
marketed herbal products still limited. To support the government 
policy, we intended to elaborate our natural resources to get some 
valuable herbal medicines.
Cassytha filiformis is among Indonesian traditional medicine that 
needs scientific approved to increase its grade to be a phytopharmaca. 
This Lauraceae family is a parasite on a variety of plants, such mango 
(Mangifera indica), clove (Eugenia aromatica), nutmeg (Myristica 
fragrans), avocado (Persea americana), and others [3]. It contains 
bioactive compounds, such as alkaloids, phenol, saponin, flavonoids, 
terpenoids, and tannin [4,5].
Conventionally, C. filiformia is used to treat jellyfish bites, to induce 
childbirth, anticancer [3]. Scientific researches described that this 
plant produced antitrypanosomal activity [5], and antibacterial [6], 
while our previous study indicated that this plant produced an 
anti-hypertension effect [7,8] anticoagulant [9], antipyretic, and 
analgesic activities [10]. In addition, antidiabetes [11,12], 
vasorelaxant [13], antioxidant, and hepatoprotection [14] also have 
been reported.
Besides some advantages, all herbal drugs are not safe; some may 
be poisonous or may cause allergenic reactions [15] or effect to one 
with gestation, both to the mother and the fetus [16]. C. filiformis is 
slightly toxic and produced delayed toxicity [17], reversible toxic to the 
liver [18], but both ethyl acetate and butanol fractions are irreversibly 
toxic to the kidney [19].
These research objectives are to evaluate the impact of C. filiformis 
butanol fraction to the development of pregnancy and fetus on mice. 
This is done to develop safe herbal medicines as required by the WHO 
2014–2023 policy [20].
METHODS
The fraction was made from the C. filiformis herbs that were collected 
from the area of Padang city (identification was made by Andalas 
University Herbarium, Padang, Indonesia No. 0912/K-ID/ANDA/2011).
The study protocol was approved by the Andalas Animal Ethics 
Committee (approval number: 323/KEP/FK/2018). A total of 36 
pregnant female white mice (indicated by vaginal plug) were divided 
into four groups consisting of one control group and three other groups 
treated with C. filiformis fraction orally at doses of 2.5, 5, and 10 mg/kg of 
body weight (BW) for 5 days during the first, second, and third trimesters 
of pregnancy. On day 18, the animals were killed and the laparotomy 
was made to measure the fetal number, weight, and fetal defect. The 
fetal defect was measure after they were fixed in Bouin and red alizarin 
solutions (Taylor et al., 2005). The parent BW was observed during the 
experiment. Data of parents’ BW were analyzed by three-way ANOVA 
while others were analyzed by two-way ANOVA. These analyses were 
followed by Duncan’s multiple range test with a 95% confidence interval.
RESULTS AND DISCUSSION
Results
Parent BW was significantly (p<0.001) affected by the period of 
treatment, dose of fraction and the duration of pregnancy and the 
interaction of those factors (Fig. 1).
The average change of BW of pregnant mice treated with the fraction 
during the first period was lower, compared to those treated during 
the second and third periods of gestation. The reduction of the BW was 
also dose-dependent (p<0.01). In this situation, the development of 
pregnancy of mice treated with the butanol fraction of C. filiformis at 
2.5 mg/kg BW during the period 1 and 5 mg/kg during the period 2 of 
gestation was faster than the other treated group at the same period. 
The development of pregnancy during the third period of gestation was 
almost equal in all group. In addition, all mice showed some progress 
in weight development day by day, during 18 days of the experiment. 
The average percentage changes in the parent BW of control group, and 
the butanol fraction treated group during the first, second, and third 
periods of pregnancy, as seen in Fig. 1.
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Butanol fraction of C. filiformis dose and the period of treatment 
significantly influence the number of the fetus of mice (p<0.01), but 
not the interaction of these factors (p>0.1). In general, the number 
of the fetus in the treated animal was less than those of the control 
group. In addition, there was no significant difference in the number 
of the fetus between mice treated with the different doses (p>0.1). The 
average number of the fetus of mice treated with butanol fraction of C. 
filiformis during period 1 was greater compared to those treated during 
the periods 2 and 3, but the number of the fetus of mice on average 
between periods 2 and 3 was not significantly different. The average 
number of the fetus of control mice remained higher than all treated 
animals (Fig. 2 and Table 1).
Fetal BW of C. filiformis butanol fraction treated animal was significantly 
affected by dose, the period of treatment and interaction of these two 
factors (p<0.001). The average fetal BW on mice treated with butanol 
fraction was higher compared to those of control group, and the average 
of fetal BW treated during period 1 of gestation was less than those 
treated during period 2 and 3. In this situation, fetal BW of animal 
treated at a dose of 2.5 mg/kg of butanol fraction of C. filiformis during 
period 1 and 3 was lower compared to those treated during period 2 
(Fig. 3 and Table 2).
There was no fetal defect found on all treated mice, except resorptive 
sites was found on the mice treated with 5 mg/kg of fraction and one 
dead fetus at a dose of 2.5 mg/kg and retarded fetus of the mother 
treated during the second period of gestation.
DISCUSSION
These experimental study objectives are to determine the impact of the 
butanol fraction of C. filiformis to mice during gestation period at the 
effective therapeutic repeated doses. The treatment was made such of 
gestation to determine whether it produces an adverse effect in that 
different gestational situation.
Before being treated, mice were acclimatized for 10 days to familiarize 
the animals with the experimental conditions and avoid the stress that 
could affect the final results of the study [21,22]. The nullipara female 
mice were used to obtain more fetus number [23]. Those animals have 
regular estrus cycles, to assured animal pregnancy when they are 
mated [24].
As noted everywhere, certain drug can produce an adverse effect on 
individuals during pregnancy, both to the mother and the fetus [25]. This 
study provides scientific information about the impact of C. filiformis 
butanol fraction to the pregnant mice, both to the parent and the fetus.
The observation showed that most of the matted mice treated with the 
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Fig. 1: The impact of butanol fraction of Cassytha filiformis to parent body weight on mice
Table 1: Fetal number of mice treated with butanol fraction of Cassytha filiformis 
Doses mg/kg Average fetal number of mice treated during periods of pregnancy Average
1 2 3
Control 16.000±0.943 15.000±0.943 14.000±0.943 15.000±0.544b
2.5 14.000±1.633 8.000±0.943 10.000±0.943 10.667±0.703a
5 11.667±0.943 10.667±0.943 11.167±0.667a
10 10.667±0.943 10.000±0.943 10.333±0.667a
Average 15.000±0.943b 11.333±0.471a 11.167±0.471a
Data are expressed as mean ± SEM. Average data with different superscript are significantly different (P<0.05).
Table 2: Fetal body weight of Cassytha filiformis butanol fraction treated mice
Doses (mg/kg) Average fetal body weight (gram) of mice treated during periods Average
1 2 3
Control 0.736±0.012 0.741±0.012 0.834±0.013 0.770±0.007a
2.5 0.839±0.022 1.213±0.017 1.147±0.015 0.996±0.011c
5 0.812±0.014 0.951±0.015 0.883±0.010b
10 0.800±0.015 0.904±0.015 0.868±0.010b
Average 0.787±0.013a 0.892±0.007b 0.915±0.007c
Data are expressed as mean ± SEM. Average data with different superscript are significantly different (P<0.05).
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pregnant, except one of three mothers those treated with the lowest 
dose (2.5 mg/kg) which was where pregnant with 14 fetuses.
Mammalian fetal development passes through three main phases: 
Blastocyst formation, organogenesis, histogenesis, and maturation of 
function [26]. According to Sadler [27], during the first trimester of 
pregnancy, the morula phase, zygote is continuously divided, which 
produce two groups of cells. One cell group will become embryo’s 
body, and the other becomes complementary cells, which include 
the trophoblast, periblast, and auxiliary cells. These cells protect the 
embryo and make contact between the embryo and the parent. Many 
teratogens have the ability to inhibit this division and kill embryo, which 
was involved in blastocyst formation. However, most of the time the 
embryo survives; its subsequent development does not generally seem 
to be compromised [28,29]. That is why, when a cytotoxic compound 
is given during the first period of pregnancy, it will affect cell division 
and the morula phase formation, and thus disrupted the formed fetus 
as seen in this study, since C. filiformis contain cytotoxic compounds [4].
On the other hands, all animals treated with the fraction during 
the second trimester of pregnancy were pregnant, but with slower 
development. It is indicated by a slower increase of the parent BW, 
especially those treated with a higher dose (10 mg/kg BW) of the 
fraction. The similar situation also shown by the animal treated with a 
lower dose of C. filiformis during the first period of pregnancy.
Our previous study showed that the butanol fraction of C. filiformis 
caused a decrease of food intake associated with central nervous system 
depressant and muscle relaxant effects on mice and thus decrease the 
mice BW [17]. When the compound is given to the pregnant individual, 
such as mice in this study, similar response may be produced. When 
the mother feed intake is lower, the fuel needs of the fetus will also 
unfulfilled, and thus, fetal development will become slower. If both 
mother and fetus BW gain progress are slower, they will lead to a lower 
average parent BW, as seen in this study. This is in agree with [29] that 
poor maternal nutritional intake after the periconceptional period of 
pregnancy can negatively impact fetal genetic growth trajectory and can 
result in fetal growth restriction. Similarly, Vonnahme et al. [30] also 
describe that maternal undernutrition on the vascularity of nutrient 
transferring tissue during different stages of pregnancy effect 
pregnancy development.
Furthermore, there was no bone abnormality seen under the red 
alizarine neither with Bouin’s solution on the embryo fixation. The 
eyes, ears, feet, toes, tail, and the cleft palate seemed anatomically 
complete and normal. Unfortunately, the fetus of the mice treated with 
the 2.5 mg/kg BW during the second period of gestation grew slowly, 
and one of them found died. A similar result also found in three of 
fetus where the parent was treated with 5 mg/kg BW of the fraction. 
In addition, there was a resorptive site on the mice treated during the 
second period of gestation.
Many chemicals have the ability to penetrate animal tissue and developing 
fetus, negatively impacting the reproductive health of human [25,31]. 
According to several authors [28,31,32], fetuses are very susceptible 
to teratogenic compounds during the second trimester, also called the 
critical period of pregnancy. During this period (organogenesis phase), 
the eyes, brain, heart skeletal, urogenital, and other organs are formed. 
If the fetus defects, this will lead to fetal death and form a red mass (fetal 
resorption) because of no more totipotential properties of the cells [28]. 
That is why, when fetal damage occurred during this period, it could 
not be repaired and neither further developed. This condition is one of 
teratogenic indication of an agent [25,28,33], as also seen this study.
Treating the mice during the third period of pregnancy produce 
interesting results. All animals in the treated groups were pregnant. 
Even though the number of the fetus in the treated animal was decreased 
significantly compared to control animals, the pregnancy developed 
faster, especially those treated with 10 mg/kg BW butanol fraction. 
In this situation, mice treated with butanol fraction of C. filiformis 
produced as many as 10 fetuses, compared to those by control mice of 
14. According to McLaren and Michief [34], the number of fetus affects 
the increase in BW of mice. If the number of the fetus is higher, the 
parent BW will also be higher.
The dose-response relationship found in this study is not linear. 
Calabrese and Baldwin [35] described that the nature of the dose of the 
response generated is not something linear that allows a U-shaped dose-
response relationship, often called biphasic or hormesis. This effect is 
often found in the fields of pharmacology and toxicology [36]. The effect 
is may due to several factors, such as antagonistic effects of the mixture 
compounds available in the fraction, compounds that have different 
target and mechanism of action as well as their pharmacokinetic 
profiles, etc., that may need to further investigation.
From the above explanation, it can be concluded that the butanol 
fraction of C. filiformis produced infertility and deliberate pregnancy 
development and fetal defect on mice.
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